CryoLife Acquires Ascyrus Medical LLC, Developer of AMDS Hybrid Prosthesis

Advancements in Treating Aortic Aneurysms

CryoLife, a leading medical technology company focused on cardiac and vascular surgery, has acquired Ascyrus Medical LLC, a privately held company based in Plymouth, Minnesota. Ascyrus Medical has developed the AMDS Hybrid Prosthesis, an innovative device for treating aortic aneurysms.

CryoLife is a world leader in the development and manufacturing of bioprosthetic heart valves, surgical meshes, and other medical devices used in cardiac and vascular surgery. The company's acquisition of Ascyrus Medical will add the AMDS Hybrid Prosthesis to its portfolio of market-leading products.

AMDS Hybrid Prosthesis

The AMDS Hybrid Prosthesis is a next-generation device for treating aortic aneurysms, a life-threatening condition caused by a weakened or bulging section of the aorta, the body's main artery. The device is designed to provide a secure and durable repair while preserving the aortic valve and minimizing the risk of complications.

The AMDS Hybrid Prosthesis consists of a flexible stent frame that is covered with a biocompatible fabric. The stent is implanted into the aorta, and the fabric conforms to the shape of the aorta, creating a seal that prevents blood from leaking into the aneurysm. The device also has a built-in valve that allows blood to flow freely through the aorta.

Benefits of the AMDS Hybrid Prosthesis

The AMDS Hybrid Prosthesis offers several benefits over traditional aortic aneurysm repair techniques:

• Preserves the aortic valve, reducing the risk of complications and the need for future surgery.
• Minimizes the risk of bleeding and infection.
• Provides a durable repair that is less likely to fail.

The AMDS Hybrid Prosthesis has been used in over 1,000 patients worldwide with excellent results. The device has been shown to be safe and effective, with a low risk of complications.

CryoLife's Commitment to Innovation

CryoLife's acquisition of Ascyrus Medical is a testament to the company's commitment to innovation. CryoLife is constantly seeking out new and innovative technologies that can improve patient outcomes. The AMDS Hybrid Prosthesis is a revolutionary device that has the potential to change the way aortic aneurysms are treated.

CryoLife is a publicly traded company headquartered in Kennesaw, Georgia. The company has approximately 1,300 employees worldwide and its products are sold in over 100 countries.